

# Ghasem Ghalamfarsa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5054943/publications.pdf>

Version: 2024-02-01

57  
papers

2,500  
citations

172457

29  
h-index

206112

48  
g-index

58  
all docs

58  
docs citations

58  
times ranked

3956  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytotoxic Effect of Podophyllotoxin-Loaded Magnetic Nanoparticles on Proliferation of Colorectal (HT-29) and Breast (MCF-7) Cancer Cell Lines. <i>Current Nanomaterials</i> , 2022, 07, .	0.4	0
2	The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses. <i>Immunology and Cell Biology</i> , 2021, 99, 814-832.	2.3	18
3	Chemical composition and cytotoxic activity of the essential oil from the aerial parts of <i>Dorema aucheri</i> . <i>Journal of HerbMed Pharmacology</i> , 2021, 10, 344-350.	0.9	1
4	Patients with Covid 19 have significantly reduced CH50 activity. <i>VirusDisease</i> , 2021, 32, 681-689.	2.0	6
5	Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. <i>Immunotherapy</i> , 2021, 13, 1355-1367.	2.0	2
6	Blockage of immune checkpoint molecules increases T cell priming potential of dendritic cell vaccine. <i>Immunology</i> , 2020, 159, 75-87.	4.4	67
7	Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. <i>International Immunopharmacology</i> , 2020, 78, 106087.	3.8	33
8	Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. <i>International Journal of Biological Macromolecules</i> , 2020, 149, 487-500.	7.5	56
9	Adenosine and adenosine receptors in colorectal cancer. <i>International Immunopharmacology</i> , 2020, 87, 106853.	3.8	24
10	Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib. <i>Life Sciences</i> , 2020, 259, 118150.	4.3	22
11	Coinhibition of S1PR1 and GP130 by siRNA-loaded alginate-conjugated trimethyl chitosan nanoparticles robustly blocks development of cancer cells. <i>Journal of Cellular Physiology</i> , 2020, 235, 9702-9717.	4.1	19
12	Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T cell responses. <i>Journal of Cellular Physiology</i> , 2020, 235, 10068-10080.	4.1	30
13	Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102240.	3.3	23
14	Silencing of HIF-1 $\beta$ /CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. <i>European Journal of Pharmacology</i> , 2020, 882, 173235.	3.5	48
15	Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine. <i>Journal of Controlled Release</i> , 2020, 326, 63-74.	9.9	56
16	Silencing of p68 and STAT3 synergistically diminishes cancer progression. <i>Life Sciences</i> , 2020, 249, 117499.	4.3	31
17	PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. <i>Life Sciences</i> , 2020, 247, 117437.	4.3	33
18	Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152915.	2.3	39

#	ARTICLE	IF	CITATIONS
19	Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression. <i>International Journal of Pharmaceutics</i> , 2020, 581, 119236.	5.2	50
20	Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. <i>International Immunopharmacology</i> , 2020, 83, 106446.	3.8	30
21	Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. <i>International Immunopharmacology</i> , 2020, 84, 106471.	3.8	18
22	Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. <i>Life Sciences</i> , 2019, 237, 116952.	4.3	69
23	S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 467-487.	3.8	37
24	Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2019, 144, 106338.	1.9	79
25	An immunoproteomic approach to identifying immunoreactive proteins in <i>Leishmania infantum</i> amastigotes using sera of dogs infected with canine visceral leishmaniasis. <i>Pathogens and Global Health</i> , 2019, 113, 124-132.	2.3	10
26	Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. <i>International Journal of Biological Macromolecules</i> , 2019, 133, 436-445.	7.5	58
27	CD73 as a potential opportunity for cancer immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 127-142.	3.4	102
28	The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 5478-5487.	4.1	41
29	Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 9943-9955.	4.1	29
30	Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9300-9314.	2.6	23
31	Association of single nucleotide autophagy-related protein 5 gene polymorphism rs2245214 with susceptibility to non-small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1924-1931.	2.6	13
32	A review on medicinal plant extracts and their active ingredients against methicillin-resistant and methicillin-sensitive <i>Staphylococcus aureus</i> . <i>Journal of HerbMed Pharmacology</i> , 2019, 8, 173-184.	0.9	12
33	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 2032-2057.	4.1	116
34	The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1415-1424.	5.6	201
35	Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population. <i>Immunology Letters</i> , 2018, 204, 16-22.	2.5	22
36	Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. <i>Journal of Cellular Physiology</i> , 2018, 233, 7165-7177.	4.1	56

#	ARTICLE	IF	CITATIONS
37	IL-27: Friend or Foe in the Autoimmune Diseases. <i>Current Immunology Reviews</i> , 2018, 13, .	1.2	1
38	Nanoparticles and targeted drug delivery in cancer therapy. <i>Immunology Letters</i> , 2017, 190, 64-83.	2.5	374
39	Safflower Seed Oil, Containing Oleic Acid and Palmitic Acid, Enhances the Stemness of Cultured Embryonic Neural Stem Cells through Notch1 and Induces Neuronal Differentiation. <i>Frontiers in Neuroscience</i> , 2017, 11, 446.	2.8	14
40	Differential Immune Reactivity Pattern of SW48 and SW1116 Colorectal Cancer Cell Lines with Colorectal Cancer Patients Sera. <i>Advanced Biomedical Research</i> , 2017, 6, 6.	0.5	3
41	A review study on phytochemistry and pharmacology applications of <i>Juglans Regia</i> plant. <i>Pharmacognosy Reviews</i> , 2017, 11, 145.	1.2	71
42	Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. <i>Journal of Immunotoxicology</i> , 2016, 13, 603-619.	1.7	38
43	IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis. <i>Journal of Immunotoxicology</i> , 2016, 13, 274-285.	1.7	31
44	Synergistic induction of apoptosis in B-cell chronic lymphocytic leukemia cells after treatment with all-trans retinoic acid in combination with interleukin-21 and rituximab. <i>Journal of Cancer Research and Therapeutics</i> , 2016, 12, 1278.	0.9	4
45	The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2015, 99, 35-40.	2.2	9
46	All-Trans-Retinoic Acid Differentially Regulates Proliferation of Normal and Leukemic B Cells From Different Subsets of Chronic Lymphocytic Leukemia. <i>Nutrition and Cancer</i> , 2015, 67, 285-291.	2.0	7
47	Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. <i>Tumor Biology</i> , 2015, 36, 5727-5742.	1.8	96
48	The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2015, 11, 1567-1582.	2.4	25
49	Myeloid-derived suppressor cells in B cell malignancies. <i>Tumor Biology</i> , 2015, 36, 7339-7353.	1.8	53
50	The Effects of NDRG2 Overexpression on Cell Proliferation and Invasiveness of SW48 Colorectal Cancer Cell Line. <i>Iranian Journal of Medical Sciences</i> , 2015, 40, 430-9.	0.4	9
51	N-myc downstream regulated gene 2 overexpression reduces matrix metalloproteinase-2 and -9 activities and cell invasion of A549 lung cancer cell line in vitro. <i>Iranian Journal of Basic Medical Sciences</i> , 2015, 18, 773-9.	1.0	11
52	The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis = Ø£Ù†Ù...Ù\$Ø© Ø\$Ù,,Ø£Ù†Ø²Ù\$Ù...Ø\$Ø³ Ø\$Ù,,Ù...Ø¹Ø¹Ù\$Ø© Ø\$Ù,,Ù...ØÙ,,Ù,,Ø© Ù,,Ù,,Ø±Ø¹Ø¹Ù\$Ù† Ù\$Ø³Ø¹Ø¹Ø¹.	1.0	55
53	Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. <i>Innovations in Clinical Neuroscience</i> , 2014, 11, 23-36.	0.1	13
54	Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. <i>Tumor Biology</i> , 2013, 34, 2031-2039.	1.8	48

#	ARTICLE	IF	CITATIONS
55	The role of natural killer T cells in B cell malignancies. <i>Tumor Biology</i> , 2013, 34, 1349-1360.	1.8	40
56	Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. <i>Cytokine</i> , 2013, 62, 439-445.	3.2	20
57	Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. <i>Tumor Biology</i> , 2013, 34, 929-940.	1.8	60